Latest information and updates about COVID-19 (coronavirus) from McMaster University
Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster Logo McMaster logo

Scleroderma Research Program

Research Admin Offices:

  • ROADS
  • HRS

Funding Type:

Grant

Value:

  1. Idea Development Award: $300,000
    • New Investigator Collaboration Option: $450,000
  2. Translational Partnership Research Award: $750,000

Disciplines:

  • Health Sciences
  • Natural Sciences and Engineering

Sponsors:

Deadlines:

Internal Deadline:

Continuous

Sponsor Deadline:

Continuous

Description:

The FY20 Defense Appropriations Act provides funding to the Department of Defense Scleroderma Research Program (SRP) to support innovative, high-impact scleroderma research.

Applications submitted to the FY20 SRP Idea Development Award must address one or more of the following Focus Areas:

  • Development of clinical trial platforms that enable the rapid comparison of different therapeutic approaches on a pilot basis
  • Define biomarkers (‘omics and/or molecular markers, cell subsets, imaging, patient-reported outcomes) that help inform choice therapeutics (immunosuppressive/anti-fibrotic) or predict course (morbidity, mortality) and quality of life
  • Secondary analysis of genomics and other datasets (scleroderma and datasets from other similar diseases), integration to identify novel targets and biomarkers to create a more analyzable set of data that can be validated in existing or new models

Applications submitted to the FY20 SRP Translational Partnership Research Award must address one or more of the following Focus Areas:

  • Understanding the different biological/metabolic pathways that differentiate subsets of patients (gender, age, genetic, clinical phenotype, race/ethnicity)
  • Utilizing systems biology and multi-omics approaches for understanding disease heterogeneity, primary prevention, therapeutics, interventions, and screening
  • Development of cohorts from diverse populations (longitudinal) to validate potential biomarkers (i.e., replication studies)
  • Define biomarkers (‘omics, and/or molecular markers, cell subsets, imaging, patient-reported outcomes) that help inform choice of therapeutics (immunosuppressive/anti-fibrotic) or predict course (morbidity, mortality) and quality of life
  • Defining epigenetic changes, multiple cell types, and molecules that mediate pathogenesis 

Deadlines

Internal Notice of Intent

Draft Application

26 August

20 November

Sponsor Preproposal

Final Application

09 September

04 December

Additional Program Information:

1. Idea Development Award

  • Supports conceptually innovative, high-risk/
    potentially high-reward research that could ultimately lead to critical discoveries and/or improvements in patient care and/or quality of life.
  • Innovation and impact are important aspects of the award.
  • Clinical trials are not allowed.
  • Preliminary data are required.
  • New Investigator Collaboration Option: Supports the continued development of promising independent investigators that are early in their faculty appointment through collaboration with an established scleroderma investigator.
  • Submission of a preproposal is required; application submission is by invitation only.

2. Translational Research Partnership Award

  • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in scleroderma into clinical applications. At least one partner must be a laboratory scientist and at least one partner must be a clinician.
  • One investigator must be a New Investigator.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • Submission of a preproposal is required; application submission is by invitation only.

 

Eligibility:

1. Idea Development Award

  • Independent investigators at all academic levels (or equivalent).
  • New Investigators:
    • Terminal degree must be within the last 10 years.
    • Must not have received NIH R01 funding.
    • Must not have received a New Investigator Award previously from any program within the CDMRP.

2. Translational Research Partnership Award

  • Independent investigators at all academic levels (or equivalent).
    Clinicians must be an M.D., M.D./Ph.D., or equivalent with clinical duties and/or responsibilities
  • New Investigators:
    • Terminal degree must be within the last 10 years.
    • Must not have received NIH R01 funding.
    • Must not have received a New Investigator Award previously from any program within the CDMRP.

Application/Nomination Process:

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Resources:

Program Website

Contact:

If you are applying from the Faculty of Health Sciences, please contact an Advisor from HRS.

For support with external non-industry funding, please contact Virginia Viscardi, Senior Advisor, ROADS.

Documents: